Suppr超能文献

比较 FORTA、PRISCUS 和 EU(7)-PIM 清单在识别潜在不适当药物及其对初级保健中多病老年德国人的认知功能的影响:一项多中心观察性研究。

Comparison of FORTA, PRISCUS and EU(7)-PIM lists on identifying potentially inappropriate medication and its impact on cognitive function in multimorbid elderly German people in primary care: a multicentre observational study.

机构信息

Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

BMJ Open. 2021 Sep 17;11(9):e050344. doi: 10.1136/bmjopen-2021-050344.

Abstract

OBJECTIVES

Our study aimed to assess the frequency of potentially inappropriate medication (PIM) use (according to three PIM lists) and to examine the association between PIM use and cognitive function among participants in the MultiCare cohort.

DESIGN

MultiCare is conducted as a longitudinal, multicentre, observational cohort study.

SETTING

The MultiCare study is located in eight different study centres in Germany.

PARTICIPANTS

3189 patients (59.3% female).

PRIMARY AND SECONDARY OUTCOME MEASURES

The study had a cross-sectional design using baseline data from the German MultiCare study. Prescribed and over-the-counter drugs were classified using FORTA (Fit fOR The Aged), PRISCUS (Latin for 'time-honoured') and EU(7)-PIM lists. A mixed-effect multivariate linear regression was performed to calculate the association between PIM use patients' cognitive function (measured with (LDST)).

RESULTS

Patients (3189) used 2152 FORTA PIM (mean 0.9±1.03 per patient), 936 PRISCUS PIM (0.3±0.58) and 4311 EU(7)-PIM (1.4±1.29). The most common FORTA PIM was phenprocoumon (13.8%); the most prevalent PRISCUS PIM was amitriptyline (2.8%); the most common EU(7)-PIM was omeprazole (14.0%). The lists rate PIM differently, with an overall overlap of 6.6%. Increasing use of PIM is significantly associated with reduced cognitive function that was detected with a correlation coefficient of -0.60 for FORTA PIM (p=0.002), -0.72 for PRISCUS PIM (p=0.025) and -0.44 for EU(7)-PIM (p=0.005).

CONCLUSION

We identified PIM using FORTA, PRISCUS and EU(7)-PIM lists differently and found that PIM use is associated with cognitive impairment according to LDST, whereby the FORTA list best explained cognitive decline for the German population. These findings are consistent with a negative impact of PIM use on multimorbid elderly patient outcomes.

TRIAL REGISTRATION NUMBER

ISRCTN89818205.

摘要

目的

本研究旨在评估(根据三张 PIM 清单)潜在不适当药物(PIM)的使用频率,并研究参与者中 PIM 使用与认知功能之间的关联。

设计

MultiCare 是一项纵向、多中心、观察性队列研究。

设置

MultiCare 研究位于德国的 8 个不同研究中心。

参与者

3189 名患者(59.3%为女性)。

主要和次要结果

该研究采用横断面设计,使用德国 MultiCare 研究的基线数据。使用 FORTA(适合老年人)、PRISCUS(拉丁语意为“久经考验”)和 EU(7)-PIM 清单对处方和非处方药物进行分类。采用混合效应多元线性回归计算 PIM 使用患者认知功能(用 LDST 测量)之间的关联。

结果

患者(3189 人)使用了 2152 种 FORTA PIM(平均每位患者 0.9±1.03)、936 种 PRISCUS PIM(0.3±0.58)和 4311 种 EU(7)-PIM(1.4±1.29)。最常见的 FORTA PIM 是苯丙香豆素(13.8%);最常见的 PRISCUS PIM 是阿米替林(2.8%);最常见的 EU(7)-PIM 是奥美拉唑(14.0%)。这些清单对 PIM 的评价不同,总体重叠率为 6.6%。PIM 使用量的增加与认知功能的降低显著相关,FORTA PIM 的相关系数为-0.60(p=0.002),PRISCUS PIM 的相关系数为-0.72(p=0.025),EU(7)-PIM 的相关系数为-0.44(p=0.005)。

结论

我们使用 FORTA、PRISCUS 和 EU(7)-PIM 清单对 PIM 进行了不同的识别,并发现 PIM 使用与根据 LDST 测量的认知障碍相关,其中 FORTA 清单最能解释德国人群的认知下降。这些发现与 PIM 使用对多病老年患者结局的负面影响一致。

试验注册号

ISRCTN89818205。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e71/8451296/142eac3cea49/bmjopen-2021-050344f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验